Clinical trials: High-Risk Cancer
Neoplasms, Ovarian
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
The purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator's choice (IC) chemotherapy in female participants with platinum-resistant HGS…
- Trial name
- NCT05613088
- Testing
- MORAb-202, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD)
- Where
- 50 sites in United States, Australia and 7 more
- Volunteers
- 106 people
- Sponsor
- Bristol-Myers Squibb
Mantle Cell Lymphoma
Observational Study for Patients With Newly Diagnosed (MCL) Not Eligible for High-dose Therapy
This is an observational study aimed to analyze the effectiveness of treatment of patients with newly dg. mantle cell lymphoma not eligible for high-dose therapy and autologous stem cell transplantation.
- Trial name
- NCT03054883
- Volunteers
- 73 people
- Sponsor
- Czech Lymphoma Study Group
Ovarian Cancer
The Efficacy and Safety of Paclitaxel Monotherapy Versus Paclitaxel-Carboplatin Combination as Neoadjuvant Chemotherapy in Advanced Ovarian Cancer With High PARK2 Expression
Platinum-based neoadjuvant chemotherapy (NACT) followed by interval debulking surgery is a crucial treatment paradigm for advanced ovarian cancer.
- Trial name
- NCT07401654
- Testing
- Paclitaxel, Paclitaxel + Carboplatin
- Volunteers
- 60 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
B Cell Lymphoma, Lymphoma
Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma
A Phase IB/II Trial of Lenalidomide (Revlimid®), Ixazomib and Rituximab (RIXAR) as Front-line Therapy for High Risk Indolent B cell Lymphoma
- Trial name
- NCT02898259
- Testing
- Ixazomib, Lenalidomide, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Brian Hill
Breast Neoplasm
Estrogen Receptor Expression in Breast Cancer - Assessed With Positron Emission Mammography
The primary objective of this study is to determine the correlation between the distribution of F-18 FES within ER+ breast tumors as seen on Positron Emission Mammography (PEM) images of the breast, and the distribution of cells…
- Trial name
- PEM-FES (NCT03266562)
- Testing
- F-18 FES, F-18 FDG
- Where
- United States
- Sponsor
- Mayo Clinic
Prostate Cancer
Biological Investigations in Active Surveillance (BIAS) IGAR 2008 I 19 in Prostate Cancer Using High Field MRI (3 Tesla), PET, and Biomarkers
This study will use high field MRI (3 Tesla), PET and biomarker to follow prostate cancers and determine if these tests can detect cancers that become aggressive.
- Trial name
- NCT00676286
- Testing
- 3T MR Imaging, C-Choline PET Scanning, Gene Rearrangement
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- AHS Cancer Control Alberta
Nasopharyngeal Carcinoma
The Value of Post-radiation Detectable Plasma EBV DNA in High-risk Nasopharyngeal Carcinoma Patients
An additional blood test at 2-3 months after RT is a valuable biomarker in predicting treatment outcome for NPC patients. Patients with persistently detectable EBV DNA during re-staging survey 2-3 months after RT should…
- Trial name
- NCT03981224
- Volunteers
- 706 people, healthy volunteers welcome
- Sponsor
- Taichung Veterans General Hospital
Adenomatous Polyp
Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer
This phase II trial is studying how well giving acetylsalicylic acid together with eflornithine works in treating patients at high risk for colorectal cancer.
- Trial name
- NCT00983580
- Testing
- Aspirin, Eflornithine, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 107 people
- Sponsor
- National Cancer Institute (NCI)
Effects of Immunotherapy, Metastatic/Recurrent Cervical Cancer
Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
To evaluate the tolerability and safety of axalimogene filolisbac 1 x 10^10 colony forming units (cfu) administered with prophylactic premedication in repeating 3-dose study cycles in women with persistent, metastatic, or…
- Conditions
- Effects of Immunotherapy, Metastatic/Recurrent Cervical Cancer, Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma
- Trial name
- NCT02164461
- Testing
- Axalimogene filolisbac
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Advaxis, Inc.
NMIBC
RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects
In this study, participants with high risk non-muscle-invasive bladder cancer (NMIBC) who are BCG Naïve or BCG Unresponsive and are considered ineligible for or have refused to undergo radical cystectomy, will receive RC48-ADC in…
- Trial name
- NCT05943379
- Testing
- RC48-ADC in Combination with gemcitabine
- Where
- China
- Volunteers
- 85 people
- Sponsor
- RemeGen Co., Ltd.
Prostate Cancer
Timing of HDR With EBRT in Localised Prostate Cancer,Toxicity and Quality of Life Assessment
TITLE Timing of HDR brachytherapy with EBRT in intermediate and high risk localised Prostate CAncer patients and its effects on Toxicity and Quality of life - randomised feasibility trial.
- Trial name
- THEPCA (NCT02618161)
- Testing
- HDR Brachytherapy, External beam Radiotherapy
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Mid and South Essex NHS Foundation Trust
High Risk Prostate Carcinoma, Prostate Cancer
Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
PEACE 7 is an international, multicenter, randomized, open-label phase III study that aims at evaluating the efficacy and safety of darolutamide and of stereotactic dose escalated prostate radiotherapy in patients with localised…
- Trial name
- PEACE 7 (NCT06625970)
- Testing
- Darolutamide, Stereotactic Body RadioTherapy (SBRT), ADT (Standard of Care)
- Where
- 6 sites in France, Martinique
- Volunteers
- 700 people
- Sponsor
- UNICANCER
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00027937
- Testing
- aldesleukin, filgrastim, sargramostim
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome
This phase II trial studies the side effects and how well liposome-encapsulated daunorubicin-cytarabine and gemtuzumab ozogamicin work in treating patients with acute myeloid leukemia that has come back (relapsed) or that does…
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome
- Trial name
- NCT03672539
- Testing
- Gemtuzumab Ozogamicin, Liposome-encapsulated Daunorubicin-Cytarabine, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Small Cell Carcinoma of Lung
Fiber-Boost Randomized Controlled Trial
In the present study 'Fiber-Boost', we investigate how a high-fiber diet affects the immunotherapy of advanced lung cancer and what effects it has on the gut microbiome (i.e., the bacteria in the gut) as well as the immune…
- Trial name
- Fiber-Boost (NCT07483112)
- Testing
- High-fiber diet
- Where
- 4 sites in Switzerland
- Volunteers
- 42 people
- Sponsor
- Cantonal Hospital of St. Gallen
Multiple Myeloma
Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells
To evaluate the overall response rate, safety, and the 12-cycle clearance rate of circulating plasma cells (CPCs) in patients with newly diagnosed transplant-ineligible multiple myeloma stratified as high-risk based on…
- Trial name
- NCT07732712
- Testing
- Isatuximab, VRD
- Volunteers
- 15 people
- Sponsor
- The Affiliated People's Hospital of Ningbo University
Cervical Cancer
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
RATIONALE: Drugs used in chemotherapy, such as cisplatin, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00980954
- Testing
- carboplatin, cisplatin, paclitaxel
- Where
- 125 sites in United States, Canada and 2 more
- Volunteers
- 236 people
- Sponsor
- Radiation Therapy Oncology Group
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
The main objective of this work is to conduct a clinical study for the development and application of a vaccine with autologous dendritic cells submitted to electroporation with Wilm's tumor 1 (WT1) messenger ribonucleic acid…
- Trial name
- NCT03083054
- Testing
- Autologous dendritic cells electroporated with WT1 mRNA
- Where
- Brazil
- Volunteers
- 5 people
- Sponsor
- University of Campinas, Brazil
Health Care Quality, Health Care Evaluation
A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid Leukemia
Patients with chronic myeloid leukemia in imatinib induced CHR are randomized between imatinib 400 mg daily and imatinib 400 mg daily + PegIntron 30 ug weekly.
- Trial name
- NCT01227356
- Testing
- imatinib and pegylated interferon
- Where
- 3 sites in Sweden
- Volunteers
- 112 people
- Sponsor
- Uppsala University
Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
This phase Ib/II trial tests the best dose of axatilimab and effectiveness of axatilimab with or without azacitidine for the treatment of patients with advanced phase myeloproliferative neoplasms (MPN), myeloproliferative…
- Conditions
- Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myelodysplastic/Myeloproliferative Neoplasm
- Trial name
- NCT06523556
- Testing
- Axatilimab, Azacitidine, Biospecimen Collection
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Uma Borate
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.